Stockreport

Sutro Biopharma GAAP EPS of -$1.78 beats by $1.31, revenue of $153.73M beats by $101.4M [Seeking Alpha]

Vaxcyte, Inc.  (PCVX) 
PDF As of year-end 2023, Sutro had cash and investments of $333.7 million and shares of Vaxcyte common stock valued at $41.9 million, which together provide a projected cas [Read more]